Published 09/27/2024 8:16:15 p.m.

Lilly gets traditional FDA approval for Retevmo for thyroid cancer (NYSE:LLY)

Summary by Seeking Alpha

Eli Lilly (LLY) has received traditional approval for its drug Retevmo for the treatment of medullary thyroid cancer with a RET mutation. Read more here.

0 Articles

All

Left

Center

Right

Seeking Alpha

Lilly gets traditional FDA approval for Retevmo for thyroid cancer (NYSE:LLY)

Eli Lilly (LLY) has received traditional approval for its drug Retevmo for the treatment of medullary thyroid cancer with a RET mutation. Read more here.

09/27/2024 10:03:02 p.m.·United States

Read Full Article

onclive.com

FDA Approves Selpercatinib for RET Fusion–Positive Medullary Thyroid Cancer

The FDA has granted traditional approval to selpercatinib (Retevmo) for advanced or metastatic medullary thyroid cancer with a RET mutation.

09/27/2024 7:23:11 p.m.

Read Full Article

Pharmacy Times

FDA Approves Selpercatinib For Pediatric and Adult Patients With RET-Mutated MTC

The indication is for adult and pediatric patients aged 2 years and older with advanced or metastatic RET-mutated medullary thyroid cancer (MTC) who require systemic therapy.

09/27/2024 8:16:15 p.m.

Read Full Article

targetedonc.com

FDA Grants Traditional Approval to Selpercatinib in RET+ Medullary Cancer

The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary thyroid cancer in patients aged 2 years and older.

09/27/2024 8:32:00 p.m.

Read Full Article